Statistics from Altmetric.com
The aim of the NAVIGATOR study was to determine whether the risk of diabetes and cardiovascular events could be reduced in people with impaired glucose tolerance using nateglinide in addition to a lifestyle modification programme.
Nine thousand three hundred and six adults with impaired glucose tolerance and either cardiovascular disease or cardiovascular risk factors were enrolled in this study and randomly assigned, with the use of an interactive voice-response telephone system, to nateglinide at a dose of 60 mg three times daily or placebo in addition to participation in a lifestyle modification programme. Both the participants and the investigators were unaware of the treatment assignments. Participants returned …
Competing interests None.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.